Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

pembrolizumab 74Cyclophosphamide 49Cisplatin 46Nivolumab 36Paclitaxel 33Radiotherapy 32Carboplatin 31Gemcitabine 30Docetaxel 27Dexamethasone 24atezolizumab 22Bevacizumab 21Blood Specimen Collection 20Lenalidomide 19Etoposide 19Radiosurgery 18Magnetic Resonance Spectroscopy 18Leucovorin 18Fluorouracil 18Doxorubicin 18fludarabine 17Surveys and Questionnaires 17Rituximab 17Vincristine 16Oxaliplatin 16Cytarabine 16Ipilimumab 15palbociclib 14durvalumab 14Radiotherapy, Intensity-Modulated 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × efineptakin alfa × 90 days × Clear all
NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NeoImmuneTech

Phase 1/2 Completed
215 enrolled 30 charts
BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡